Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

STK33 kinase activity is nonessential in KRAS-dependent cancer cells.

Babij C, Zhang Y, Kurzeja RJ, Munzli A, Shehabeldin A, Fernando M, Quon K, Kassner PD, Ruefli-Brasse AA, Watson VJ, Fajardo F, Jackson A, Zondlo J, Sun Y, Ellison AR, Plewa CA, San MT, Robinson J, McCarter J, Schwandner R, Judd T, Carnahan J, Dussault I.

Cancer Res. 2011 Sep 1;71(17):5818-26. doi: 10.1158/0008-5472.CAN-11-0778.

2.

Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells.

Scholl C, Fröhling S, Dunn IF, Schinzel AC, Barbie DA, Kim SY, Silver SJ, Tamayo P, Wadlow RC, Ramaswamy S, Döhner K, Bullinger L, Sandy P, Boehm JS, Root DE, Jacks T, Hahn WC, Gilliland DG.

Cell. 2009 May 29;137(5):821-34. doi: 10.1016/j.cell.2009.03.017.

3.

Targeting of KRAS mutant tumors by HSP90 inhibitors involves degradation of STK33.

Azoitei N, Hoffmann CM, Ellegast JM, Ball CR, Obermayer K, Gößele U, Koch B, Faber K, Genze F, Schrader M, Kestler HA, Döhner H, Chiosis G, Glimm H, Fröhling S, Scholl C.

J Exp Med. 2012 Apr 9;209(4):697-711. doi: 10.1084/jem.20111910.

4.

STK33 kinase inhibitor BRD-8899 has no effect on KRAS-dependent cancer cell viability.

Luo T, Masson K, Jaffe JD, Silkworth W, Ross NT, Scherer CA, Scholl C, Fröhling S, Carr SA, Stern AM, Schreiber SL, Golub TR.

Proc Natl Acad Sci U S A. 2012 Feb 21;109(8):2860-5. doi: 10.1073/pnas.1120589109.

5.

Screen for Inhibitors of STK33 Kinase Activity.

Spoonamore J, Weïwer M, Wei J, Guichard B, Ross NT, Masson K, Silkworth W, Dandapani S, Munoz B, Palmer M, Scherer C, Schreiber SL.

Probe Reports from the NIH Molecular Libraries Program [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2010-.
2011 Dec 16 [updated 2014 May 13].

6.

STK33 kinase is not essential in KRAS-dependent cells--letter.

Fröhling S, Scholl C.

Cancer Res. 2011 Dec 15;71(24):7716; author reply 7717. doi: 10.1158/0008-5472.CAN-11-2495. No abstract available.

7.

Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers.

Ebi H, Corcoran RB, Singh A, Chen Z, Song Y, Lifshits E, Ryan DP, Meyerhardt JA, Benes C, Settleman J, Wong KK, Cantley LC, Engelman JA.

J Clin Invest. 2011 Nov;121(11):4311-21. doi: 10.1172/JCI57909.

8.

Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab.

Dunn EF, Iida M, Myers RA, Campbell DA, Hintz KA, Armstrong EA, Li C, Wheeler DL.

Oncogene. 2011 Feb 3;30(5):561-74. doi: 10.1038/onc.2010.430.

9.

Synergistic effect between erlotinib and MEK inhibitors in KRAS wild-type human pancreatic cancer cells.

Diep CH, Munoz RM, Choudhary A, Von Hoff DD, Han H.

Clin Cancer Res. 2011 May 1;17(9):2744-56. doi: 10.1158/1078-0432.CCR-10-2214.

10.

Phosphorylation at Ser-181 of oncogenic KRAS is required for tumor growth.

Barceló C, Paco N, Morell M, Alvarez-Moya B, Bota-Rabassedas N, Jaumot M, Vilardell F, Capella G, Agell N.

Cancer Res. 2014 Feb 15;74(4):1190-9. doi: 10.1158/0008-5472.CAN-13-1750.

11.

Knockdown of oncogenic KRAS in non-small cell lung cancers suppresses tumor growth and sensitizes tumor cells to targeted therapy.

Sunaga N, Shames DS, Girard L, Peyton M, Larsen JE, Imai H, Soh J, Sato M, Yanagitani N, Kaira K, Xie Y, Gazdar AF, Mori M, Minna JD.

Mol Cancer Ther. 2011 Feb;10(2):336-46. doi: 10.1158/1535-7163.MCT-10-0750.

12.

RAF suppression synergizes with MEK inhibition in KRAS mutant cancer cells.

Lamba S, Russo M, Sun C, Lazzari L, Cancelliere C, Grernrum W, Lieftink C, Bernards R, Di Nicolantonio F, Bardelli A.

Cell Rep. 2014 Sep 11;8(5):1475-83. doi: 10.1016/j.celrep.2014.07.033.

13.

Determination of synthetic lethal interactions in KRAS oncogene-dependent cancer cells reveals novel therapeutic targeting strategies.

Steckel M, Molina-Arcas M, Weigelt B, Marani M, Warne PH, Kuznetsov H, Kelly G, Saunders B, Howell M, Downward J, Hancock DC.

Cell Res. 2012 Aug;22(8):1227-45. doi: 10.1038/cr.2012.82.

14.

Ribonucleoprotein HNRNPA2B1 interacts with and regulates oncogenic KRAS in pancreatic ductal adenocarcinoma cells.

Barceló C, Etchin J, Mansour MR, Sanda T, Ginesta MM, Sanchez-Arévalo Lobo VJ, Real FX, Capellà G, Estanyol JM, Jaumot M, Look AT, Agell N.

Gastroenterology. 2014 Oct;147(4):882-892.e8. doi: 10.1053/j.gastro.2014.06.041.

PMID:
24998203
15.

Coordinate direct input of both KRAS and IGF1 receptor to activation of PI3 kinase in KRAS-mutant lung cancer.

Molina-Arcas M, Hancock DC, Sheridan C, Kumar MS, Downward J.

Cancer Discov. 2013 May;3(5):548-63. doi: 10.1158/2159-8290.CD-12-0446.

16.

A gene expression signature of RAS pathway dependence predicts response to PI3K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors.

Loboda A, Nebozhyn M, Klinghoffer R, Frazier J, Chastain M, Arthur W, Roberts B, Zhang T, Chenard M, Haines B, Andersen J, Nagashima K, Paweletz C, Lynch B, Feldman I, Dai H, Huang P, Watters J.

BMC Med Genomics. 2010 Jun 30;3:26. doi: 10.1186/1755-8794-3-26.

17.

Oncogenic KRAS-induced epiregulin overexpression contributes to aggressive phenotype and is a promising therapeutic target in non-small-cell lung cancer.

Sunaga N, Kaira K, Imai H, Shimizu K, Nakano T, Shames DS, Girard L, Soh J, Sato M, Iwasaki Y, Ishizuka T, Gazdar AF, Minna JD, Mori M.

Oncogene. 2013 Aug 22;32(34):4034-42. doi: 10.1038/onc.2012.402.

18.

A CDK4/6 inhibitor enhances cytotoxicity of paclitaxel in lung adenocarcinoma cells harboring mutant KRAS as well as wild-type KRAS.

Zhang XH, Cheng Y, Shin JY, Kim JO, Oh JE, Kang JH.

Cancer Biol Ther. 2013 Jul;14(7):597-605. doi: 10.4161/cbt.24592.

19.

A Potent and Selective Quinoxalinone-Based STK33 Inhibitor Does Not Show Synthetic Lethality in KRAS-Dependent Cells.

Weïwer M, Spoonamore J, Wei J, Guichard B, Ross NT, Masson K, Silkworth W, Dandapani S, Palmer M, Scherer CA, Stern AM, Schreiber SL, Munoz B.

ACS Med Chem Lett. 2012 Dec 13;3(12):1034-1038.

20.

3-phosphoinositide-dependent kinase 1 controls breast tumor growth in a kinase-dependent but Akt-independent manner.

Gagliardi PA, di Blasio L, Orso F, Seano G, Sessa R, Taverna D, Bussolino F, Primo L.

Neoplasia. 2012 Aug;14(8):719-31.

Supplemental Content

Support Center